コンテンツへスキップ
Merck

RAB0555

Human PLAU  / Urokinase-type Plasminogen Activator ELISA Kit

for serum, plasma, cell culture supernatants and urine

別名:

PLAU ELISA Kit, Urokinase Detection Kit

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

NACRES:
NA.32
UNSPSC Code:
41116158
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

Human PLAU  / Urokinase-type Plasminogen Activator ELISA Kit, for serum, plasma, cell culture supernatants and urine

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable

input

sample type urine
sample type plasma
sample type serum
sample type cell culture supernatant(s)

assay range

inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 10 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... PLAU (5328)

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

General description

The antibody pair provided in this kit detects Human uPA in serum, plasma, cell culture supernatants, and urine.

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

pictograms

Corrosion

signalword

Warning

hcodes

Hazard Classifications

Met. Corr. 1

保管分類

8A - Combustible corrosive hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Hongwei Zhou et al.
Oncology letters, 14(5), 5189-5196 (2017-11-09)
The overexpression of the oncogene human epidermal growth factor receptor 2 (HER-2) has been associated with decreased disease-free survival and is a marker of poor prognosis of invasive breast cancer. Although the high efficacy of trastuzumab, a drug that targets
C Ostheimer et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 194(6), 539-551 (2018-01-18)
The urokinase plasminogen activator system (uPA, uPAR, PAI‑1) is upregulated in cancer and high plasma levels are associated with poor prognosis. Their interaction with hypoxia-related osteopontin (OPN) which is also overexpressed in malignant tumors suggests potential clinical relevance. However, the
Tomasz W Kaminski et al.
International urology and nephrology, 50(1), 127-135 (2017-10-24)
Chronic kidney disease (CKD) is an estimated risk factor for increased mortality and morbidity due to fibrinolytic system disturbances. Progressive loss of renal function leads to retention of uremic toxins. Anthranilic acid (AA) is a tryptophan-derived uremic toxin with multidirectional
Lutz Beckert et al.
JCI insight, 5 (2019-04-19)
Current dosing of intrapleural fibrinolytic therapy (IPFT) in adults with complicated parapneumonic effusion (CPE) / empyema is empiric, as dose-escalation trials have not previously been conducted. We hypothesized that LTI-01 (scuPA), which is relatively resistant to PA inhibitor-1 (PAI-1), would
Anastasia Gabrielyan et al.
Stem cell research & therapy, 8(1), 212-212 (2017-10-04)
The main goal of bone tissue engineering has been the generation of healthy bone in order to replace affected tissue. Therefore, optimized biomaterials are needed which allow the survival and growth of mesenchymal stem cells. Until now the key challenge

関連コンテンツ

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)